Compare MUX & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MUX | EVO |
|---|---|---|
| Founded | 1979 | 1993 |
| Country | Canada | Germany |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | MUX | EVO |
|---|---|---|
| Price | $18.61 | $3.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $21.63 | $7.00 |
| AVG Volume (30 Days) | ★ 1.2M | 250.1K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $166,453,000.00 | ★ $887,396,457.00 |
| Revenue This Year | $3.15 | N/A |
| Revenue Next Year | $43.83 | $8.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.38 | $2.84 |
| 52 Week High | $24.88 | $4.80 |
| Indicator | MUX | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.13 | 48.75 |
| Support Level | $19.05 | $3.03 |
| Resistance Level | $20.22 | $3.18 |
| Average True Range (ATR) | 1.03 | 0.08 |
| MACD | -0.10 | 0.03 |
| Stochastic Oscillator | 14.11 | 72.58 |
McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.